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Germline Mutations in the Extracellular Domains
of the 55 kDa TNF Receptor, TNFR1, Define a Family
of Dominantly Inherited Autoinflammatory Syndromes
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McDermott et al., 1997). Mulley et al. (1998) have charac- et al., 1994; Peschon et al., 1998b), suggesting that the
proinflammatory effects of TNF are mediated predomi-terized a large Australian pedigree of Scottish ancestry
with a similar condition, denoting it familial periodic fever nantly through the p55 receptor.
Ligand-independent self-association of TNFR1 cyto-(FPF). Smaller pedigrees of other ethnic backgrounds
have also been reported. Although families exhibiting a plasmic domains is inhibited by a 60 kDa ªsilencer of
death domainsº (SODD; Jiang et al., 1999). TNF actionsdominant mode of inheritance have several common
features, including febrile episodes that often last more may also be constrained in part by metalloprotease-
dependent cleavage of membrane-bound TNF recep-than one week, there are clinical differences among
them, most notably the types of skin rash and the pres- tors (Porteu and Nathan, 1990; Crowe et al., 1995; MuÈ ll-
berg et al., 1995), which can be triggered by a numberence or absence of amyloidosis. Thus, it has not been
clear whether the dominant periodic fevers represent of proinflammatory stimuli. Cleavage is thought to con-
tribute to the clearance of TNFR1 and TNFR2 from theone or more mutations at a single locus, or result from
mutations in several genes. membrane, and produces a pool of soluble receptors
that may attenuate the inflammatory response by com-Genome-wide searches for susceptibility loci have
been independently performed on the Irish/Scottish FHF peting with membrane-bound receptors (Engelmann et
al., 1989). Mice homozygous for a targeted mutationfamily (with two other Irish families) as well as the Austra-
lian FPF family of Scottish descent. Disease loci in these in an enzyme that cleaves several membrane proteins
(including TNF and TNFR2) have numerous develop-families were recently mapped to distal chromosome
12p (McDermott et al., 1998; Mulley et al., 1998), with mental defects (Peschon et al., 1998a), emphasizing the
physiologic importance of ectodomain shedding.FPF localized by recombination to the z19 cM between
D12S364 and D12S314, and FHF mapped to the z11 Given the central role of TNFR1 in inflammation, its
location within the FHF/FPF interval, and the observa-cM between D12S77 and D12S93 (which is totally sub-
sumed within the FPF interval). These data suggest that tion of abnormal levels of soluble p55 in patients' blood,
we hypothesized that gain-of-function mutations in thisthe same locus may underlie disease susceptibility in
all of the families studied, and raise the possibility that gene might explain dominantly inherited periodic fever
in at least some families. Here we report the identifica-this locus might also account for susceptibility in other
similar pedigrees. tion of six different missense coding mutations in seven
families of varied ethnic backgrounds, including the fourBased on recent transcript maps (Deloukas et al.,
1998), there are a number of plausible positional candi- pedigrees recently linked to chromosome 12p13. Five of
these mutations involved cysteines participating in di-date genes within the D12S77-D12S93 FHF/FPF interval,
including CD4, LAG-3, CD27, and the complement sulfide bonds in the first and second extracellular TNFR1
domains, while the sixth substituted a methionine for agenes C1R and C1S. In addition, one of the two known
receptors for the proinflammatory cytokine tumor necro- highly conserved threonine adjacent to a cysteine in-
volved in disulfide bonding. In considering mechanismssis factor (TNF) is encoded within the candidate region.
by which these mutations might induce inflammation,This 55 kDa receptor (p55, TNFR1, CD120a; Loetscher
we evaluated several possibilities, including (1) in-et al., 1990; Schall et al., 1990) is widely expressed on
creased affinity of mutant TNFR1 for ligand; (2) constitu-a number of cell types. A second, 75 kDa receptor (p75,
tive activation, possibly through the formation of inter-TNFR2, CD120b; Smith et al., 1990) is found predomi-
molecular disulfide bonds between unpaired cysteinesnantly on leukocytes and endothelial cells and is en-
in mutant receptors (Santoro et al., 1995); and (3) resis-coded on chromosome 1p.
tance of mutant TNFR1 to the normal homeostatic ef-We took a particular interest in the TNFR1 gene be-
fects of activation-induced cleavage. Analysis of leuko-cause of preliminary observations on the prototype FHF
cytes from the three affected members of a family withfamily suggesting that between attacks FHF patients
a C52F mutation favors the third possibility.have reduced blood levels of a soluble form of TNFR1
relative to healthy controls, and that during attacks these
Resultslevels increase much less than in other inflammatory
conditions. TNFR1 was also an attractive candidate be-
cause of the range of biologic actions of TNF (reviewed Mutational Analyses
The seven families studied in the present report includein Vassalli, 1992). These pleiotropic activities include
increased expression of adhesion molecules on leuko- the FPF family of Scottish ancestry recently linked to
chromosome 12p13 (Mulley et al., 1998), the prototypecytes and endothelial cell surfaces, induction of cytokine
secretion, leukocyte activation, host resistance to intra- Irish/Scottish Hibernian fever family and one large Irish
family from the FHF linkage study (McDermott et al.,cellular pathogens, angiogenesis, pyrexia, anemia, and
cachexia. Both TNFR1 and TNFR2 belong to a family 1998), a Finnish family (VaÈ limaÈ ki et al., 1985; Karenko et
al., 1992), and three small North American families ofof receptors with repeating cysteine-rich extracellular
motifs (Bazzoni and Beutler, 1996). TNF homotrimers Irish/English/German (Zaks and Kastner, 1997), Irish,
and French-Canadian ancestry. Of the four pedigreesinduce signaling by aggregation of membrane receptors
(Engelmann et al., 1990). TNFR1 contains an z70 residue that had not previously undergone microsatellite analy-
sis, only the Finnish family was large enough to permitªdeath domainº that is actually a protein±protein interac-
tion domain involved in signal transduction (Hsu et al., conclusive linkage studies. Genotypes for D12S356
yielded a maximal pairwise LOD score of 3.1 at u 5 01995). Knockout mice for TNFR1 are much more suscep-
tible to challenge with intracellular bacterial pathogens in the Finnish family, and an 11-microsatellite haplotype
spanning the FHF/FPF candidate region segregatedand bacterial lipopolysaccharide than are wild-type con-
trols (Pfeffer et al., 1993) or TNFR2 knockouts (Erickson with disease.
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Figure 1. DNA Sequence Electropherograms Demonstrating Disease-Associated TNFR1 Mutations
A summary of the mutations, including the ethnicities of the families studied and the number of control chromosomes screened, is shown in
the upper panels. Electropherograms for individuals heterozygous for the mutations are shown in the middle panels, and homozygotes for
the normal alleles are shown in the lower panels. The relevant nucleotide is indicated with a down-arrow in the middle panels.
For each family, a single nucleotide substitution was In the second extracellular domain of TNFR1, two
identified upon genomic sequencing of the coding re- mutations cause missense substitutions for the cysteine
gion and splice junctions of the TNFR1 gene (Figure 1). at residue 88. In the Australian FPF family, a mutation
Four mutations produced missense changes in the first at nt 349 in all seven of the available affected members
cysteine-rich extracellular domain of the TNFR1 protein. results in an arginine at this residue (C88R). In 4/4 af-
A mutation leading to the substitution of arginine for fected members of the Finnish family, a G→A transition
cysteine at residue 30 (relative to the signal peptide at nt 350 produces a tyrosine at this residue (C88Y). For
cleavage site) was observed in the two affected mem- these latter two mutations, control chromosomes were
bers of the Irish-American family (C30R). In 13 affected screened by restriction endonuclease digests, using
members analyzed from the prototype FHF family, a primers designed in such a way that the mutation either
G→A transition results in the substitution of tyrosine for creates (C88R) or abolishes (C88Y) a restriction site in
cysteine at residue 33 (C33Y). In one branch of this the amplified DNA. Figure 2 illustrates the use of the TaqI
family, three individuals reported to have periodic fevers assay for C88R in DNAs from affected and unaffected
did not possess the substitution, but they also did not members of the Australian FPF family. When this assay
share the microsatellite haplotype present in all other was performed on 134 Northern European control chro-
affected members, and the diagnosing clinician has not
mosomes, and when the HinP1I assay for C88Y was
witnessed the attacks of any of these three individuals.
performed on 122 Finnish control chromosomes, noneEight of eight affected members of the Irish FHF family,
were positive for the mutation.and the one available member of the French-Canadian
Altogether, these six mutations were observed in 40family, had a mutation leading to the substitution of
of 43 symptomatic family members; the three variantmethionine for threonine at residue 50 (T50M). Two of
negative individuals all belong to the same family andtwo additional members of the Irish family with mild
may represent genetic heterogeneity or misdiagnoses.symptoms also proved to have this mutation. Finally,
The T50M and C88Y mutations were each observed inthe three affected members of the Irish/English/German
a single asymptomatic adult member of the Irish andfamily had a G→T transversion that causes the substitu-
the Finnish family, respectively. The six mutations weretion of phenylalanine for cysteine at residue 52 (C52F).
not observed in any of the other 40 healthy relativesNone of these changes were found in any of over 100




Figure 2. TaqI Restriction Endonuclease Assay
for the C88R Mutation in an Australian Family
of Scottish Ancestry
The upper part of the figure depicts the pedi-
gree of this family, adapted from Mulley et
al. (1998). Filled symbols represent affected
family members; DNA was available from
numbered individuals. Genomic DNA was
PCR-amplified with a primer set designed
such that the C88R mutation creates a TaqI
restriction endonuclease cleavage site in the
amplified DNA. Amplicons were digested with
the restriction enzyme, and electrophoresed
on polyacrylamide gels. The lower part of the
figure depicts a photograph of the ethidium
bromide-stained gel from this family. Note
that all affected individuals have two bands,
and that all unaffected individuals have one
band.
Soluble p55 Receptor Levels Are Diminished 127.4 pg/ml) and normal individuals (1002.1 6 261.8
pg/ml). Nonpenetrant individuals and those with mildin the Blood of Individuals Bearing TNFR1
Extracellular Mutations symptoms all had low p55 levels, arguing that reduced
soluble p55 receptor levels are not simply a conse-The examination of TNFR1 as a positional candidate
had been encouraged by preliminary data suggesting quence of repeated episodes of inflammation, but di-
rectly related to genotype. The p55 levels varied signifi-reduced levels of soluble p55 in the blood of affected
members of the prototype FHF family. We have ex- cantly among families (F17,43 5 3.09, p , 0.001), but this
finding reflects variability only for the noncarriers (F15,18 5tended these serologic studies to a total of 27 mutation-
positive individuals with four different mutations (Table 3.47, p , 0.007), with no significant variability among
families for mutation carriers (F3,23 5 2.3, p 5 0.11). Al-1). Statistical analyses showed a highly significant
(F1,43 5 94.3, p , 0.0001) difference in p55 levels between though the mean p55 level among mutation carriers dur-
ing an attack (926.0 6 270.1 pg/ml) was significantlymutation carriers not experiencing attacks (541.6 6
Table 1. Soluble TNF Receptor Levels in Families with Dominantly Inherited Periodic Fever
Family (Mutation) p55 (TNFR1)a pb p75 (TNFR2)a pb
Prototype FHF (C33Y)
Affected, between attacks (8) 591 6 115 ,0.025 2297 6 380 1.00
Affected, during attacks (5) 889 6 284 2718 6 648
Unaffected (7)c 899 6 142 2093 6 479
Irish (T50M)
Affected, between attacks (11) 571 6 117 ,0.0001 Ð
Unaffected (9)d 1273 6 248 Ð
Finnish (C88Y)
Affected, between attacks (5) 402 6 113 ,0.0001 Ð
Unaffected (11)d 785 6 103 Ð
Irish/English/German (C52F)e
Affected, between attacks (2)f 624 6 77 3009 6 1295
Affected, during attacks (1)g 1111 6 259 3138 6 974
Controls (9)h 1077 6 215 1994 6 293
Active RA, SLE (2) 10,225 6 5324 5970 6 783
a Values are expressed as mean pg/ml 6 SD.
b Statistical significance between affecteds not experiencing attacks and unaffecteds by the paired t test.
c Two unaffected members of the same family, five healthy controls.
d Unaffected members of the same family.
e Statistics were not calculated for this family, because of the small sample size.
f Two determinations for each of two individuals.
g Four determinations for a single individual.
h Unaffected, unrelated individuals.
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Figure 3. Mutated Amino Acids Are at Highly Conserved Positions in the TNFR Superfamily
Several members of the TNF receptor family were aligned using a variation of BLAST that compares two sequences to each other. The first
ten extracellular disulfide bonds predicted by crystallographic analysis of TNFR1 (Banner et al., 1993) are numbered and shown as lines
connecting conserved cysteine residues. The amino acids in which we have observed mutations in patients are marked with asterisks and
are numbered.
greater (p , 0.02) than between attacks (541.6 6 127.4 Functional TNF Receptors Are Expressed
on Leukocytes of Patientspg/ml), elevations were much less than in the control
patients with active rheumatoid arthritis or systemic lu- with the C52F Mutation
Figure 3 depicts the alignment of TNFR1 with severalpus erythematosus.
To evaluate the possibility that reduced soluble p55 other members of this receptor family, indicating that
five of these mutations involve a conserved residuelevels might be the result of a more general deficit, solu-
ble p75 levels were also measured in two families. Levels shown crystallographically (Banner et al., 1993) to par-
ticipate in disulfide bonding. Although they are notof p55 and p75 were not correlated (r 5 0.09, p 5 0.62),
and mean levels of p75 did not significantly vary be- points of receptor±ligand contact, the five cysteine sub-
stitutions, and perhaps T50M as well, would significantlytween mutation carriers and noncarriers (p 5 0.64).
Moreover, levels of p75 were similar (p 5 0.8) between affect the structure of this molecule. If these changes
caused ubiquitination and degradation, mutated TNFR1attacks (2439.2 6 623.6 pg/ml) and during attacks
(2788.2 6 604.5 pg/ml). might never reach the cell membrane, and mutations
Figure 4. TNF Receptors on Leukocytes from
Patients with the C52F Mutation
PMNs (A and B) and monocytes (C and D)
were analyzed for CD120a (TNFR1) and
CD120b (TNFR2) expression. Single cell sus-
pensions of peripheral blood leukocytes (106
cells) were incubated with anti-CD120a-PE,
anti-CD120b-PE, or isotype-matched IgG-PE
as control (histogram 1), washed, and ana-
lyzed by flow cytometry. Histograms 4, 5, and
6 (in red) represent TNFR expression in the
three patients with the C52F mutation, and
histograms 2 and 3 (in green) show the ex-
pression in two different control donors. (E)
PMNs from patients with the C52F mutation
bind TNF. Patient (histogram 3 and 5, in red)
and control donor (histogram 2 and 4, in
green) PMNs were incubated with a FITC-
conjugated monoclonal antibody that recog-
nizes both membrane-bound TNF and TNF
bound to its receptors, or an isotype-
matched FITC-IgG control (histogram 1).
Cells were preincubated with (histogram 4
and 5) or without (histogram 2 and 3) human
recombinant TNF (1 mg/ml) for 1 hr at 48C,
washed 3 times, and incubated with anti-TNF
or control antibody for 30 min at 48C. After 3




Figure 5. Leukocytes Bearing the C52F Mutation Have Defective Clearance of TNFR1 (CD120a)
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on one allele might therefore result in the reduction in (Garcia et al., 1995), and exogenous soluble TNF recep-
tor can ameliorate inflammatory disease in experimentalsoluble p55 noted above. Figure 4 presents flow cyto-
metric data relevant to this issue in the three affected animals (Mohler et al., 1993) and humans (Moreland et
al., 1997). Impaired receptor clearance might thereforemembers of the family bearing the C52F mutation.
Somewhat unexpectedly, panels A and B indicate in- explain the autoinflammatory phenotype and the in-
creased cell surface TNFR1 in C52F patients, as well ascreased surface TNFR1 (CD120a) but not TNFR2 (CD120b)
staining in polymorphonuclear leukocytes (PMNs) from the reduced soluble p55 blood levels.
To study TNFR1 cleavage more directly, monocytesthe three individuals bearing this mutation (histograms
4±6) relative to normal controls (histograms 2 and 3). and PMNs from C52F patients and controls were treated
with 4b-phorbol 12-myristate 13-acetate (PMA), a potentSimilar data for monocytes are presented in panels C
and D. inducer of the metalloproteases mediating receptor
shedding (MuÈ llberg et al., 1995). Part A of Figure 5 com-Figure 4E explores the capacity of C52F leukocytes
to bind TNF. Comparison of histograms 2 and 3 indicates pares CD120a (TNFR1, p55) staining of monocytes from
three patients and two controls. In all three patients,that the total cell surface TNF (membrane plus receptor-
bound) was greater for the patient PMNs than normal unstimulated monocytes (histogram 2) had about 10-
fold greater staining than the controls. Histogram 3 de-controls. When recombinant TNF was added and total
membrane TNF was detected with a nonneutralizing picts CD120a staining 10 min after PMA stimulation, and
histogram 4 depicts staining 1 hr after addition of PMA.antibody, similar increases in membrane TNF were ob-
served in patient (histogram 5 versus 3) and control In normal monocytes, there was marked diminution in
membrane CD120a at 10 min and nearly complete clear-(histogram 4 versus 2) PMNs, thus confirming the capac-
ity of receptors on the patients' cells to bind ligand. ance by 1 hr. By contrast, there was virtually no reduc-
tion in CD120a staining at either time point in the pa-Experiments not shown in the figure demonstrated that
C52F PMNs pretreated with blocking antibodies against tients' monocytes.
Part B of Figure 5 depicts the results of similar studiesTNFR2 bound biotinylated TNF at levels comparable to
controls. Although the autoinflammatory phenotype of on PMNs. Unstimulated patient cells had substantially
more surface CD120a than controls, and addition ofthese patients would be consistent with a heightened
affinity of mutant receptors for their ligand, binding stud- PMA resulted in a rapid and complete reduction of stain-
ing in the controls. Ten minutes after addition of PMAies of 125I-labeled TNF to PMNs demonstrated a Kd of
448 6 79 pM for three C52F patients, which was not there was minimal attenuation of staining in all three
patients; at the 1 hr time point, staining of the patients'significantly different from the value of 618 6 266 pM
measured in five controls. Although these figures proba- PMNs had diminished, but there were still substantial
levels of CD120a.bly represent the average affinity of several species of
mutant/wild-type receptor combinations, they do not Panel C summarizes the PMN data at the 10 min time
point, sharply contrasting the minimal reductions insupport the hypothesis that inflammatory attacks are
caused by heightened affinity of receptor for TNF. CD120a in C52F patients with the substantial attenua-
tion observed in healthy controls. Moreover, leukocytesWe also considered the possibility that the C52F mu-
tation could cause constitutive activation, perhaps by from patients with active systemic lupus erythematosus
or rheumatoid arthritis, which expressed high levels ofpermitting intermolecular disulfide homodimerization
and ligand-independent activation (Santoro et al., 1995). TNFR1, cleared CD120a promptly. Panel D demon-
strates that both C52F patients and controls had similarTo test this hypothesis, purified peripheral blood mono-
nuclear cells were stimulated with varying concentra- PMA-induced reductions in CD16 staining, thus ruling
out a more general defect in clearance.tions of TNF, and supernatants were assayed for IL-6, a
TNF-responsive cytokine. Baseline IL-6 production was To determine whether the in vitro stimulation system
would recapitulate the diminished soluble p55 levelsnot increased, and the dose±response for purified
mononuclear cells was similar to controls (data not observed in vivo, we performed ELISA assays for soluble
p55 on supernatants of PMA-stimulated leukocytes. Theshown), thus arguing against constitutive activation.
results are shown in Figure 6. Shed p55 ectodomain
levels were markedly lower in supernatants of patientsImpaired Clearance of Membrane TNFR1
in Patients with the C52F Mutation relative to healthy controls at all time points (panel A)
and over a broad range of PMA doses (panel B), despiteMembrane TNFR1 is regulated in part by metallopro-
tease-mediated cleavage. Shed receptors retain ligand- the fact that p55 was expressed at much higher levels
on patients' cells. Panel C shows several determinationsbinding activity and may have an anti-inflammatory
effect by competing for TNF binding with membrane re- of shed p55 receptor. Whereas cells from the C52F pa-
tients had reduced levels of receptor shedding, patientsceptors (Engelmann et al., 1989). Moreover, transgenic
mice expressing high levels of a TNFR1 fusion protein with active autoimmune disease had increased PMA-
induced TNFR1 shedding, thus reinforcing the point thatare resistant to several of the biological effects of TNF
Monocytes (A) and PMNs (B) were analyzed for CD120a expression, before (histogram 2) or after PMA activation (10 ng/ml) for 10 min
(histogram 3) or 1 hr (histogram 4). Single cell suspensions (106 cells) were incubated with anti-CD120a-PE, or isotype-matched IgG-PE as
control (histogram 1), washed, and analyzed by flow cytometry. (C and D) Cells were stained with PE-coupled anti-CD120a (C) or FITC-coupled
anti-CD16 (D) before and after PMA activation (10 min, 10 ng/ml) and analyzed by flow cytometry. Mean fluorescence intensity was measured
in control donors (green, open circles), C52F mutation patients (red, filled circles), or autoimmune patients (shaded diamonds).
Cell
140
Figure 6. Leukocytes Bearing the C52F Mu-
tation Have Impaired Shedding of TNFR1
(p55) as Detected by ELISA
(A and D) Peripheral blood cells from control
donors (open circles) or C52F patients (filled
circles) were stimulated with PMA (100 ng/
ml) for 5, 10, 30, and 60 min (A and D). (B and
E) Cells from controls (open circles) or C52F
patients (filled circles) were activated for 1 hr
with increasing doses of PMA. (C and F) Cells
from control donors (open circles), from C52F
patients (filled circles), or from autoimmune
patients (shaded diamonds) were activated
for 1 hr with PMA (10 ng/ml). Supernatants
were collected and soluble TNFR1 (p55; A±C)
and TNFR2 (p75; D±F) were measured by
ELISA.
impaired clearance is not an inevitable consequence of their absence in healthy family members or in any of a
large panel of control chromosomes, all argue that thesesystemic inflammation.
Panels D±F present similar analyses for TNFR2, the substitutions are not benign polymorphisms. Moreover,
we have demonstrated functional abnormalities in thep75 receptor. In contrast to p55, shedding of p75 was
greater in patient samples than in controls at 10 and 20 membrane-bound p55 TNF receptors of patients with
the C52F mutation, thereby suggesting a probable mecha-min after PMA stimulation (panel D). A dose±response
at 1 hr indicated nearly identical p75 receptor shedding nism by which this mutation causes disease.
The autosomal dominant periodic fevers thereforebetween patient and control samples at all doses of
PMA (panel E). Panel F demonstrates that, unlike p55, represent a class of human disease shown to be caused
by mutations in TNF receptors. Autoantibodies are notp75 shedding in C52F patients was consistently in the
high±normal range, at levels comparable to autoimmune a general feature of these illnesses or the recessively
inherited FMF, and for this reason the term autoinflam-patients.
matory is preferable to autoimmune in describing these
disorders. Variation in ethnic background, pattern ofDiscussion
cutaneous involvement, and presence of systemic amy-
loidosis have created uncertainty about the etiology andIn this paper, we present compelling evidence that muta-
tions in the extracellular domains of TNFR1 can cause classification of the dominantly inherited periodic fevers.
The identification of TNFR1 mutations in several familiesa dominantly inherited syndrome of episodic fever and
inflammation. In each of seven different families we have of disparate ethnic backgrounds and clinical pheno-
types is a persuasive argument for a nomenclature thatdemonstrated a missense point mutation predicted to
have a profound effect on the structure of TNFR1 by unifies those families sharing this common pathogene-
sis. We propose the descriptive acronym TRAPS (TNFdisrupting highly conserved intrachain disulfide bonds.
The identification of six independent disease-associ- receptor-associated periodic syndromes) to include all
cases with documented TNFR1 mutations, while re-ated abnormalities in the same gene, the clustering of
these substitutions within two cysteine-rich motifs, and taining historical names (FHF, FPF, etc.) to denote indi-
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vidual variants or for clinical diagnosis. The identification with the loss of a C-terminal cytoplasmic negative regu-
latory domain. Atopy has been associated with codomi-of six independent receptor mutations is inconsistent
with a major founder effect in TRAPS. nant inheritance of an IL-4a receptor polymorphism,
which may impair binding of intracellular negative regu-This report also suggests impaired cytokine receptor
clearance as a novel mechanism of human disease. In latory phosphatases (Hershey et al., 1997).
Data from patients bearing the C52F TNFR1 mutationthe three affected members of a family with the C52F
mutation, we found markedly increased cell-surface suggest that the TRAP syndromes are likely to be due
to a mechanism different from those described above.TNFR1 relative to healthy controls. Stimulation with
PMA, which induces metalloprotease-mediated cleav- In the patients presented here, a mutation affecting the
first extracellular domain impairs the normal regulatoryage of TNFR1, resulted in much less clearance of mem-
brane receptor in these patients than in controls, and processes of membrane clearance and ectodomain
shedding, while the intracellular signaling domain ofdiminished shedding of receptor ectodomain into the
supernatant. Control experiments with CD16 and TNFR2 TNFR1 is intact. The C52F TNFR1 mutation appears to
be a novel type of dominant negative, in which ªnega-refuted the possibility of a generalized defect in receptor
clearance, and studies of patients with active autoim- tiveº refers not to a failure of signaling, but instead to
a failure of shedding. It may serve as a paradigm notmune disease confirmed prior evidence for increased
receptor shedding with systemic inflammation (reviewed only for those TRAPS families in which we have not
formally explored the mechanism of disease, but forin Aderka, 1996). Moreover, for the family with C52F
and others with different mutations, circulating levels of additional as yet undiscovered mutations in other mem-
bers of the TNF receptor family. Mutations in Fas, an-TNFR1 between inflammatory episodes were lower than
those of healthy controls, and the increased levels ob- other member of the TNF receptor family, can cause a
dominantly inherited syndrome of lymphoproliferationserved during attacks were substantially less than would
be observed in other inflammatory diseases. and autoimmunity, but the mutations identified to date
have not involved this mechanism (Drappa et al., 1995;We therefore propose that the C52F mutation inter-
feres with normal homeostasis both by impairing post- Fisher et al., 1995; Rieux-Laucat et al., 1995).
TRAPS patients can have disease-free intervals ofstimulatory TNF receptor clearance, and by reducing
levels of shed soluble receptor that can compete with months to years, suggesting that the mutated protein
functions adequately much of the time and requires anthe membrane form. TNF directly stimulates p55 shed-
ding from monocytes and induces receptor shedding important environmental triggering event for disease. In
some cases the factors associated with attacks fit wellfrom PMNs via other proinflammatory intermediates
(Porteu and Hieblot, 1994). Site-directed mutagenesis of with our understanding of TNF pathways, as when mild
infections or localized trauma provoke a prolonged sys-TNFR1 suggests that the most likely target of activation-
induced receptor cleavage is Asn-172±Val-173 (Gullberg temic inflammatory episode. For other frequently men-
tioned inciting factors, such as psychological stress andet al., 1992), which is spatially remote from the mutations
described here. Possibly, TRAPS mutations cause con- physical exertion, or protective factors, such as preg-
nancy, the connection with TNF is less well-established.formational changes in TNFR1 that interfere with metal-
loprotease binding. Alternatively, interchain disulfide Given that we have observed six different mutations
in seven families, it is premature to speculate on whetherbonds may form between unpaired cysteines, resulting
in steric inhibition of metalloprotease interactions, or phenotypic variation correlates with specific mutations
in TNFR1, or with other background genes segregatingnecessitating two proteolytic ªhitsº for clearance of
membrane TNFR1 homodimers. in these families. Particularly important is the question
of whether certain TNFR1 mutations predispose to sys-For certain other cytokine receptors, interchain disul-
fide bonds at specific residues can cause constitutive, temic amyloidosis, a potentially life-threatening compli-
cation. The amyloidosis of TRAPS is caused by the tis-ligand-independent activation (Watowich et al., 1992;
Alexander et al., 1995; Santoro et al., 1995). Ligand- sue deposition of a product of the acute phase reactant
serum amyloid A (SAA), which is produced by hepato-independent activation is unlikely in TRAPS, given the
episodic clinical course and our inability to observe cytes in response to TNF and IL-6. Arguing against a
direct genotype±phenotype correlation is the fact thatspontaneous IL-6 production by C52F mononuclear
cells. Constitutive overexpression of human p75 TNFR2 although the C33Y and C52F mutations both disrupt
the third disulfide bond in the first extracellular domain,in transgenic mice results in a ligand-independent lethal
wasting disease (Douni and Kollias, 1998). The present amyloidosis has developed in all adult members of the
C52F family, but in only 1 of 21 affected members ofclinical and laboratory data are inconsistent with consti-
tutive TNFR1 activation in the C52F patients, though the family with the C33Y mutation. In contrast with muta-
tions of the Fas gene (Fisher et al., 1995), TNFR1 muta-more subtle effects remain to be examined, and this
mechanism may be important in TRAPS patients with tions are nearly completely penetrant, with only 2/42 (5%)
mutation-positive individuals reporting no symptoms.other mutations.
TRAPS also stands out as one of the few dominantly Observation of TRAPS patients will complement stud-
ies of transgenic and knockout mice in deepening ourinherited disorders of cytokine receptors described to
date. Systemic mastocytosis can be caused by a gain- understanding of the inflammatory cascade. Particularly
intriguing are questions related to the predilection ofof-function cytoplasmic substitution in c-Kit, the recep-
tor for stem cell ligand, leading to constitutive autophos- TRAPS attacks for certain anatomic sites, such as the
serosa, joints, and conjunctivae. A recent clinical analy-phorylation (Nagata et al., 1995). Dominantly inherited
erythrocytosis can result from truncating mutations in sis of the prototypic FHF family (C33Y) demonstrated
that 8/10 affected males had inguinal hernias, versusthe erythropoietin receptor (de la Chapelle et al., 1993),
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found, we treated family effects as a random component for subse-1/21 unaffected male family members (McDermott et al.,
quent analysis of variance procedures. We tested whether there1997). One female member of the Irish C30R family de-
were differences between mutation carriers and noncarriers usingveloped a severe neurologic illness in her childhood that
a mixed effects analysis of variance design in which family member-
has persisted into adult life, a finding that may be related ship was treated as a random component and mutation status was
to neurologic abnormalities reported in TNF receptor treated as a fixed effect. To compare mutation carriers during and
between attacks, we used paired and two-sample t tests. For theknockout mice (Bruce et al., 1996). In contrast to TNF
two-sample t test using p55 levels, interindividual variance duringtransgenic mice (Keffer et al., 1991), TRAPS patients
attacks was significantly greater than the variance between attacks,have not been observed to develop erosive arthritis.
and so we used a t test assuming unequal variances. Where avail-Laboratory studies of leukocytes from TRAPS patients
able, replicate observations for an individual were averaged. Statisti-
will also extend our understanding of TNF-mediated sig- cal analyses were completed using the Statistical Analysis System
naling and apoptosis. Treatment of patients with newly (SAS).
developed TNF inhibitors, such as the recombinant p75
TNFR:Fc fusion protein (Moreland et al., 1997) or the Mutation Detection by Fluorescent Sequencing
cA2 chimeric monoclonal antibody (Elliott et al., 1994; Approximately 100 ng of genomic DNA template was used in PCR
Targan et al., 1997), will further delineate the biologic reactions to amplify exons (Fuchs et al., 1992) and flanking intronic
sequences according to the supplier's recommendations for Ampli-role of TNF in these patients, while providing a rational
Taq Gold (Perkin Elmer) or the Advantage-GC Genomic PCR Kittherapeutic approach to a condition for which there have
(Clontech). The PCR primers were tailed with either 221 M13 for-been few options.
ward, TGTAAAACGACGGCCAGT, or 228 M13 reverse, AGGAAA
Thus, the findings presented in this paper define TRAPS CAGCTATGACCAT. Forward (F) and reverse (R) oligonucleotides
as a new class of autoinflammatory disease, establish used to amplify exons were as follows (all sequences are given 59
impaired cytokine receptor clearance as a novel patho- to 39): exon 1F, ACTTGGGACGTCCTGGACAGACC; exon 1R, GGA
AGGTGCCTCGCCCACCAG (193 bp); exon 2/3F, CCTCTCTTGATGGgenetic mechanism, and promise to extend our under-
TGTCTCC; exon 2/3R, CTGACTCTCCTGCCTGTGC (575 bp); exonstanding of the TNF cascade in health and disease. In
4/5F, GGTATGTCAGGAAGGGGATG; exon 4/5R, CAGTGCCCAGClight of the central role TNF plays in inflammation, it is
AGCTCTC (546 bp); exon 6/7F, CAATGGTAGGGCCTCTGTTC; exon
likely that additional TNF receptor mutations, or muta- 6/7R, CACCCATGTCCTCCCTCAC (430 bp); exon 8/9F, TGATGCTTT
tions of molecules upstream or downstream in the TNF CTTTCTTTTTC; exon 8/9R, CAGCCTCCTCGTCTCCAG (577 bp).
pathway, may be found in a range of other inflammatory Exon 10 was amplified in two overlapping fragments: exon 10AF,
GGACCACGAGAGGCGGAG; exon 10AR CCATCCCAGCAGCTCdiseases.
CAGCGT (291 bp); exon 10BF, ATCGATCGGCTGGAGCTGCAG; exon
10BR, ACCCCTCCTTTCCAGAAAAA (296 bp). PCR products were
Experimental Procedures sequenced by dye primer chemistry (Amersham) on an ABI 377
automated sequencer as described (International FMF Consortium,
Patients and DNA Samples 1997).
Clinical details and pedigrees of five of the seven families studied
in this report have been previously described (Karenko et al., 1992;
Restriction Endonuclease Assays for TNFR1 MutationsMcDermott et al., 1997; Zaks and Kastner, 1997; family B in McDer-
Restriction endonuclease assays were developed for five of themott et al., 1998; Mulley et al., 1998). Samples were also obtained
mutations reported here. For each assay, 50±100 ng of genomicfrom one affected member of a French-Canadian family and two
DNA was amplified in a total volume of 10 ml in the presence of 1.5affected siblings from an Irish-American family. A total of 85 individu-
mmol MgCl2 PCR buffer, 0.04 U AmpliTaq Gold, and 1 pmol of eachals were studied, 41 of whom had been judged to be affected by
of the appropriate PCR primers. For C33Y, the exon 2/3F primer wasclinical criteria (McDermott et al., 1997; Mulley et al., 1998), and an
used with TCCACTTGCCCCTACCTTTGTAG; for T50M, the primersadditional 2 of whom had mild symptoms. Consent was obtained
were TGTGTTCTCACCCGCAGCCTAAC (F) and TCTCACACTCCCTfrom study participants after approval of the human experimentation
GCAGTAC (R); for C52F, the T50M forward primer was used withcommittees at each institution. DNA was extracted from whole blood
the exon 2/3R primer; for C88R, the primers were TTACAGAGACAor transformed lymphocytes by standard techniques.
CACACTTAGG (F) and CACGGTGTCCCGGTCCACTGTTC (R); and
for C88Y, the C88R forward primer was used with CACGGTGTCCCGGenotyping and Linkage Analysis
GTCCACTGCG. PCR began with 958C for 10 min, followed by 30DNAs from the Finnish, Irish, and prototype FHF family were geno-
cycles of 958C for 30 s, 558C (T50M) or 608C (C33Y, C52F, C88R,typed for 11 microsatellites spanning the FHF/FPF candidate region.
and C88Y) for 30 s, and 728C for 30 s, with the final extension atFrom telomere to centromere, these were D12S341, D12S93,
728C for 10 min. The amplified products were digested for at leastD12S99, D12S356, D12S374, TNFR55, CD4, D12S397, D12S1695,
2 hr with 10 units of the appropriate restriction endonuclease. Re-D12S77, and D12S358. PCR amplifications were performed as de-
striction digests were as follows: C33Y, ScaI (mutation creates site);scribed (McDermott et al., 1998); sequences of oligonucleotides and
T50M, SnaBI (mutation abolishes site); C52F, PstI (mutation abol-specific conditions used to amplify these markers are available from
ishes site); C88R, TaqI (mutation creates site); and C88Y, HinP1Ithe Genome Database, except for TNFR55, for which the primers
(mutation abolishes site). Samples were loaded on 4%±20% poly-were 59 CACAGTCTCTCCTGTATCAT 39 (forward) and 59 CCTTC
acrylamide gels (Novex) and stained with ethidium bromide.TGAATTTCTCACC 39 (reverse). LOD scores were calculated as de-
scribed (McDermott et al., 1998).
Cell Activation and Flow Cytometric Analysis
Blood cells or neutrophils sedimented through Ficoll-Hypaque gra-Measurement of Soluble TNF Receptors
Soluble TNFR1 (p55) and TNFR2 (p75) were measured in plasma or dients were washed and incubated at 378C for 10 min or 1 hr in
Hanks' balanced salt solution (HBSS) containing 1% fetal calf serumculture supernatants by solid-phase ELISA (R&D Systems, Minneap-
olis). For studies of plasma receptor levels, simple descriptive stud- (FCS), with or without PMA (Sigma). Cells were washed with
HBSS/1% FCS at 48C and erythrocytes were lysed using ammoniumies were completed for p55 and p75 levels to document approximate
normality. The correlation between p55 and p75 levels was assessed chloride potassium (ACK) lysing buffer (BioWhittaker). Expression
of membrane TNFR1 and TNFR2 were detected by flow cytometryby the Pearson product±moment correlation coefficient. To test
whether p55 and p75 levels varied among mutation carriers between using phycoerythrin (PE)-conjugated anti-CD120a and anti-CD120b
monoclonal antibodies (Caltag) and isotype controls (Becton Dickin-attacks, we used a fixed-effects analysis of variance procedure.
Because no significant evidence for family-specific effects was son); membrane CD16 was detected with fluorescein isothiocyanate
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(FITC)-conjugated monoclonal antibodies (Becton Dickinson). Mono- Centola, M., Aksentijevich, I., and Kastner, D.L. (1998). The heredi-
tary periodic fever syndromes: molecular analysis of a new familycytes were identified by staining with conjugated anti-CD14 mono-
of inflammatory diseases. Hum. Mol. Genet. 7, 1581±1588.clonal antibodies (Becton Dickinson), and lymphocyte, monocyte,
and neutrophil populations were analyzed after flow cytometric gat- Crowe, P.D., Walter, B.N., Mohler, K.M., Otten-Evans, C., Black,
ing. Cells were incubated with conjugated antibodies or isotype R.A., and Ware, C.F. (1995). A metalloprotease inhibitor blocks shed-
controls for 30 min at 48C and washed 3 times with phosphate- ding of the 80-kD TNF receptor and TNF processing in T lympho-
buffered saline containing 0.5% bovine serum albumin (BSA). Sam- cytes. J. Exp. Med. 181, 1205±1210.
ples were analyzed on a FACS Calibur flow cytometer (Becton Dick- de la Chapelle, A., Traskelin, A.L., and Juvonen, E. (1993). Truncated
inson). erythropoietin receptor causes dominantly inherited benign human
erythrocytosis. Proc. Natl. Acad. Sci. USA 90, 4495±4499.
Deloukas, P., Schuler, G.D., Gyapay, G., Beasley, E.M., Soderlund,TNF Binding Assays
C., Rodriguez-TomeÂ , P., Hui, L., Matise, T.C., McKusick, K.B., Beck-Serial dilutions of 125I-TNF (2000±62.5 pM; NEN Life Science) were
mann, J.S., et al. (1998). A physical map of 30,000 human genes.added to 2.2 3 106 cells in a final volume of 200 ml (RPMI 1640,
Science 282, 744±746.1% BSA) and incubated for 4 hr on ice. Background binding was
measured in the presence of a 200-fold molar excess of cold ligand. Douni, E., and Kollias, G. (1998). A critical role of the p75 tumor
Bound ligand was determined by centrifuging the cells through a necrosis factor receptor (p75TNF-R) in organ inflammation indepen-
dibutylphthalate/bis(2-ethylhexyl)phthalate (60:40) cushion and cut- dent of TNF, lymphotoxin a, or the p55TNF-R. J. Exp. Med. 188,
ting off the tip of the tube to count the bound radioactivity. 1343±1352.
Drappa, J., Vaishnaw, A.K., Sullivan, K.E., Chu, J.-L., and Elkon,
K.B. (1995). Fas gene mutations in the Canale-Smith syndrome, anTNF In Vitro Stimulation Assays
inherited lymphoproliferative disorder associated with autoimmu-Peripheral blood mononuclear cells were isolated by centrifugation
nity. N. Engl. J. Med. 335, 1643±1649.on Ficoll-Hypaque gradients. The cells were washed and resus-
Drenth, J.P.H., Mariman, E.C.M., van der Velde-Visser, S.D., Ropers,pended at a concentration of 106/ml in RPMI 1640 supplemented
H.H., van der Meer, J.W.M., and the International Hyper-IgD Studywith 10% heat-inactivated FCS, penicillin/streptomycin, and 2 mM
Group (1994). Location of the gene causing hyperimmunoglobuli-L-glutamine; 1 ml cultures were established in 24-well plates
nemia D and periodic fever syndrome differs from that for familial(Costar). Cells were cultured with medium alone or with TNF (9, 18,
Mediterranean fever. Hum. Genet. 94, 616±620.90, 180, 900, and 1800 pg/ml) for 48 hr. Cell-free supernatants were
collected by centrifugation and analyzed by ELISA for IL-6 (R&D Elliott, M.J., Maini, R.N., Feldmann, M., Long-Fox, A., Charles, P.,
Systems). Bijl, H., and Woody, J.N. (1994). Repeated therapy with monoclonal
antibody to tumour necrosis factor alpha (cA2) in patients with rheu-
matoid arthritis. Lancet 344, 1125±1127.Acknowledgments
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